Immunome (IMNM) News Today $9.90 -1.24 (-11.13%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Piper Sandler Lowers Immunome (NASDAQ:IMNM) Price Target to $21.00November 16 at 3:47 AM | americanbankingnews.comImmunome Inc. Announces Third Quarter 2024 Financial Results and Pipeline ProgressNovember 16 at 2:10 AM | americanbankingnews.comWedbush Sticks to Their Buy Rating for Immunome (IMNM)November 15 at 9:48 AM | markets.businessinsider.comImmunome (NASDAQ:IMNM) Stock Price Down 7% on Analyst DowngradeImmunome (NASDAQ:IMNM) Stock Price Down 7% on Analyst DowngradeNovember 14 at 11:36 AM | marketbeat.comPiper Sandler Cuts Immunome (NASDAQ:IMNM) Price Target to $21.00Piper Sandler reduced their price target on Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a report on Thursday.November 14 at 8:48 AM | marketbeat.comPromising Growth Potential for Immunome: Buy Rating Backed by Strategic Acquisitions and Innovative PipelineNovember 14 at 3:09 AM | markets.businessinsider.comImmunome Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finance.yahoo.comImmunome initiated with an Overweight at StephensNovember 9, 2024 | markets.businessinsider.comAnalyst Expectations For Immunome's FutureNovember 9, 2024 | benzinga.comStephens & Co. Initiates Coverage of Immunome (IMNM) with Overweight RecommendationNovember 9, 2024 | msn.comImmunome (NASDAQ:IMNM) Shares Gap Up - Still a Buy?Immunome (NASDAQ:IMNM) Shares Gap Up - Time to Buy?November 8, 2024 | marketbeat.comStephens Begins Coverage on Immunome (NASDAQ:IMNM)Stephens began coverage on Immunome in a research note on Friday. They set an "overweight" rating and a $30.00 price target for the company.November 8, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Trading Up 8.7% - Here's What HappenedImmunome (NASDAQ:IMNM) Trading Up 8.7% - Still a Buy?November 4, 2024 | marketbeat.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | businesswire.comImmunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by AnalystsShares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have received an average recommendation of "Buy" from the six research firms that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages thNovember 1, 2024 | marketbeat.comImmunome Advances with Strategic Asset Acquisition and AgreementOctober 30, 2024 | finance.yahoo.comImmunome, Inc. (NASDAQ:IMNM) Sees Significant Decrease in Short InterestImmunome, Inc. (NASDAQ:IMNM - Get Free Report) was the target of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 10,920,000 shares, a decline of 15.2% from the September 30th total of 12,880,000 shares. Currently, 22.3% of the shares of the stock are short sold. Based on an average trading volume of 649,500 shares, the days-to-cover ratio is currently 16.8 days.October 29, 2024 | marketbeat.comWedbush Remains a Buy on Immunome (IMNM)October 25, 2024 | markets.businessinsider.comImmunome (NASDAQ:IMNM) Stock Rating Reaffirmed by WedbushWedbush reiterated an "outperform" rating and set a $33.00 price target on shares of Immunome in a report on Friday.October 25, 2024 | marketbeat.comImmunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR SymposiumOctober 18, 2024 | businesswire.comCubist Systematic Strategies LLC Reduces Stake in Immunome, Inc. (NASDAQ:IMNM)Cubist Systematic Strategies LLC reduced its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 73.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,421 shares of the company's stock after selOctober 15, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Grows Stock Position in Immunome, Inc. (NASDAQ:IMNM)The Manufacturers Life Insurance Company increased its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 52.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 166,928 shares of the company's stockOctober 10, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Trading Down 6.1% - Time to Sell?Immunome (NASDAQ:IMNM) Stock Price Down 6.1% - Should You Sell?October 9, 2024 | marketbeat.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 8, 2024 | finance.yahoo.comImmunome (NASDAQ:IMNM) Trading Up 3.5% - Here's What HappenedImmunome (NASDAQ:IMNM) Stock Price Up 3.5% - Should You Buy?October 8, 2024 | marketbeat.comImmunome Appoints Roee Shahar as Executive Vice President, CommercialOctober 8, 2024 | finance.yahoo.comSquarepoint Ops LLC Sells 45,843 Shares of Immunome, Inc. (NASDAQ:IMNM)Squarepoint Ops LLC decreased its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 38.3% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 73,929 shares of the company's stock after selling 45,843 shares during the period. SquarepoiOctober 7, 2024 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Receives Consensus Rating of "Buy" from AnalystsShares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have been assigned an average recommendation of "Buy" from the six ratings firms that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages thOctober 7, 2024 | marketbeat.comCubist Systematic Strategies LLC Sells 54,117 Shares of Immunome, Inc. (NASDAQ:IMNM)Cubist Systematic Strategies LLC cut its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 73.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,421 shares of the company's stOctober 6, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comImmunome, Inc. (NASDAQ:IMNM) Stock Holdings Cut by Point72 Asset Management L.P.Point72 Asset Management L.P. lessened its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 76.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 385,067 shares of the company's stock after selling 1,256,833 shares during tOctober 2, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Down 4.7% Immunome (NASDAQ:IMNM) Stock Price Down 4.7%October 1, 2024 | marketbeat.comAxa S.A. Invests $2.17 Million in Immunome, Inc. (NASDAQ:IMNM)Axa S.A. acquired a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 179,688 shares of the company's stock, valued at approximately $2,174,000. AxaOctober 1, 2024 | marketbeat.comNortheast Financial Consultants Inc Buys Shares of 72,953 Immunome, Inc. (NASDAQ:IMNM)Northeast Financial Consultants Inc purchased a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 72,953 shares of the company's stock, valued aSeptember 29, 2024 | marketbeat.comMarshall Wace LLP Has $20.73 Million Stake in Immunome, Inc. (NASDAQ:IMNM)Marshall Wace LLP lifted its position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 228.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,713,325 shares of the company's stock after buying an additionSeptember 27, 2024 | marketbeat.comIMNM Jan 2025 17.500 callSeptember 24, 2024 | ca.finance.yahoo.comRhumbline Advisers Acquires Shares of 67,184 Immunome, Inc. (NASDAQ:IMNM)Rhumbline Advisers acquired a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 67,184 shares of the company's stock, valued at approximately $813,000. Rhumbline Advisers owned about 0.11% of ImmunoSeptember 24, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Down 5.6% After Insider SellingImmunome (NASDAQ:IMNM) Stock Price Down 5.6% After Insider SellingSeptember 23, 2024 | marketbeat.comIMNM Oct 2024 45.000 putSeptember 22, 2024 | ca.finance.yahoo.comImmunome CFO sells shares valued at over $230,000September 21, 2024 | in.investing.comImmunome, Inc. (NASDAQ:IMNM) CFO Max Rosett Sells 14,380 SharesSeptember 21, 2024 | insidertrades.comPrimecap Management Co. CA Purchases 55,800 Shares of Immunome, Inc. (NASDAQ:IMNM)Primecap Management Co. CA increased its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 26.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 268,800 shares of the company's stock after acquiring an additionalSeptember 19, 2024 | marketbeat.comBank of New York Mellon Corp Takes $1.82 Million Position in Immunome, Inc. (NASDAQ:IMNM)Bank of New York Mellon Corp acquired a new position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 150,100 shares of the company'September 18, 2024 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Shares Bought by Sofinnova Investments Inc.Sofinnova Investments Inc. grew its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 10.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 655,680 shares of the company's stock after acquiring an additional 61,September 17, 2024 | marketbeat.comTD Cowen Sticks to Its Buy Rating for Immunome (IMNM)September 17, 2024 | markets.businessinsider.comVictory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM)Victory Capital Management Inc. raised its holdings in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 39.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 493,288 shares of the company's stock afterSeptember 16, 2024 | marketbeat.comTD Asset Management Inc Increases Holdings in Immunome, Inc. (NASDAQ:IMNM)TD Asset Management Inc boosted its holdings in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 13.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 325,206 shares of the company's stock after acqSeptember 12, 2024 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Given Average Rating of "Buy" by BrokeragesImmunome, Inc. (NASDAQ:IMNM - Get Free Report) has earned a consensus recommendation of "Buy" from the six analysts that are presently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokeragesSeptember 12, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Trading 6.9% Higher Immunome (NASDAQ:IMNM) Shares Up 6.9%September 9, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Down 4% Immunome (NASDAQ:IMNM) Stock Price Down 4%September 4, 2024 | marketbeat.com Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics… Get Your Free Gold Guide IMNM Media Mentions By Week IMNM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMNM News Sentiment▼-0.090.56▲Average Medical News Sentiment IMNM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMNM Articles This Week▼94▲IMNM Articles Average Week Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IGMS News Today VIR News Today ENLV News Today LBPH News Today ARWR News Today IDYA News Today KROS News Today NAMS News Today CGON News Today TWST News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMNM) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
